Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyAetna Intravenous Iron Coverage & Prior Auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0575

    Intravenous Iron Therapy

    Customize your policy alerts

    Sign up for Aetna Policy 0575 alerts

    Get alerted when Policy 0575 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage policy for intravenous iron products for Aetna commercial medical plans, defining medically necessary indications, required precertification for certain products, and brand-selection rules. Affects providers treating members with iron deficiency anemia.

    Policy Summary
    PayerAetna
    PolicyIntravenous Iron Therapy
    Policy CodePolicy 0575
    Change TypeNo material change
    Effective DateNov 13, 2001
    Last ReviewFeb 1, 2024
    Next Review DateDec 12, 2024
    Key ActionObtain precertification prior to billing Injectafer, Monoferric, or Feraheme and document ferritin/TSAT and prior oral iron intolerance or inadequate response.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    0575Policy number
    3 productsPrecertification required
    MultipleProducts covered
    02/01/2024Last review

    Coverage Criteria for Intravenous Iron Products

    Injectafer (ferric carboxymaltose) — Initial approval

    Aetna considers Injectafer medically necessary for the following when criteria are met.

    Age and documented IDA

    • Scenarios for IV need: Any of: members losing iron (eg heavy uterine bleeding or autologous donation), gastrointestinal disorders (eg IBD: ulcerative colitis, Crohn's), repeated inability/nonadherence to oral iron, decreased absorption after gastric bypass/subtotal gastric resection
    Injectafer for specific adult diagnoses: Treatment of members 18 years and older with documented iron deficiency and either non-dialysis dependent (NDD) chronic kidney disease with iron deficiency anemia OR to improve exercise capacity in NYHA II–III chronic heart failure (LVEF <45%) with iron deficiency (ferritin <100 ng/mL or ferritin 100–300 ng/mL with TSAT <20%)
    Cancer/chemotherapy-induced anemia: Management of cancer- and chemotherapy-induced anemia when any of the cancer-related iron deficiency criteria are met (see cancer/chemotherapy-induced anemia criteria)

    Coding and Diagnostic Thresholds

    Covered HCPCS/CPT codes (examples)mixedCovered
    J1439Injection, ferric carboxymaltose, 1 mg
    J1437Injection, ferric derisomaltose, 10 mg
    J1750Injection, iron dextran, 50 mg
    Q0138Injection, Ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-ESRD use)
    Q0139Injection, Ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for ESRD on dialysis)
    0251UHepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma
    96365-96368Intravenous infusion administration
    96372Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
    96374-96379Intravenous push administration
    ICD-10 codes associated with covered indicationsICD-10
    D63.0Anemia in neoplastic disease
    D63.1Anemia in chronic kidney disease
    D64.81Anemia due to antineoplastic chemotherapy
    E83.10Disorder of iron metabolism, unspecified
    K50.00-K50.919Crohn's disease
    K51.00-K51.919Ulcerative colitis
    K91.1Postgastric surgery syndromes
    N18.1-N18.9Chronic kidney disease
    N92.0-N92.4Excessive and frequent menstruation / excessive menstruation at puberty / excessive bleeding in premenopausal period
    N95.0Postmenopausal bleeding
    1–10 of 18
    1/2
    Covered HCPCS Codes (when selection criteria met)HCPCSCovered
    J1750Injection, iron dextran, 50 mg
    J1756Injection, iron sucrose, 1 mg
    J2916Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg

    Provider Actions, Prior Authorization and Documentation

    Prior Authorization

    Precertification Required for Select Brands

    Precertification is required for ferric carboxymaltose (Injectafer), ferric derisomaltose (Monoferric), and ferumoxytol injection (Feraheme). To precertify, call (866) 752-7021 or fax (888) 267-3277. Use the Statement of Medical Necessity (SMN) precertification forms available on the Specialty Pharmacy Precertification webpage.

    • Applies to all Aetna participating providers and members in applicable plan designs
    • Required for Injectafer, Monoferric, and Feraheme
    Prior Authorization

    Prior Authorization for IV Iron Products

    Prior authorization is required for IV iron products billed with covered HCPCS/CPT codes when selection criteria in this policy are not clearly met. Provide clinical documentation to demonstrate medical necessity and adherence to policy criteria.

    • Prior authorization applies when billing the listed J-codes/HCPCS for IV iron
    • Documentation should include rationale for IV use versus oral therapy when applicable

    Background and Clinical Context

    Iron deficiency anemia (IDA) is a spectrum with differing diagnostic thresholds depending on clinical context. In non‑inflammatory settings, serum ferritin <30 ng/mL or transferrin saturation (TSAT) <20% generally indicates absolute iron deficiency. In inflammatory states or chronic disease (including CKD and heart failure) operational cutoffs are higher—commonly ferritin <100 µg/L, or ferritin 100–299 µg/L with TSAT <20%. The policy uses these context‑specific thresholds to guide when intravenous iron is appropriate versus when oral therapy or further evaluation is indicated.

    Definitions and Product Descriptions

    Iron deficiency anemia (IDA) — diagnostic thresholds by context
    IDA diagnostic thresholds (aggregate)Non-CKD: ferritin <30 ng/mL or TSAT <20%; NDD-CKD: ferritin <100 ng/mL or TSAT <20% (if ferritin 100–300 require TSAT <20%); HD-CKD and PD-CKD have higher ferritin/TSAT combinations as listed in policy
    Inflammation-adjusted ruleFerritin <100 µg/L OR ferritin 100–300 µg/L with TSAT <20% to define iron deficiency in inflammatory states
    CKD operational thresholdsConsider IV iron when TSAT ≤30% and ferritin ≤500 ng/mL for many CKD scenarios
    Absolute iron deficiency
    Absolute iron deficiency (definition)Serum ferritin <30 ng/mL AND TSAT <20%
    Context — NCCN concordanceNCCN defines absolute deficiency similarly for cancer-associated anemia (ferritin <30 and TSAT <20)

    Policy Dates, History and Administrative Notes

    Administrative details: this Clinical Policy Bulletin (Policy No. 0575) is effective from 11/13/2001 with the most recent review on 02/01/2024 and next scheduled review on 12/12/2024. For precertification of select products (Injectafer, Monoferric, Feraheme) providers should follow the policy’s precertification instructions and contact the specialty precertification resources as listed in the full bulletin; the policy also directs providers to include required clinical documentation (baseline hemoglobin, ferritin, TSAT, prior oral iron trial or rationale for IV therapy) when seeking authorization.

    Policy Summary
    PayerAetna
    PolicyIntravenous Iron Therapy
    Policy CodePolicy 0575
    Change TypeNo material change
    Effective DateNov 13, 2001
    Last ReviewFeb 1, 2024
    Next Review DateDec 12, 2024
    Key ActionObtain precertification prior to billing Injectafer, Monoferric, or Feraheme and document ferritin/TSAT and prior oral iron intolerance or inadequate response.
    SourceLink
    On This Page
    Coverage Criteria for Intravenous Iron ProductsCoding and Diagnostic ThresholdsProvider Actions, Prior Authorization and DocumentationBackground and Clinical ContextDefinitions and Product DescriptionsPolicy Dates, History and Administrative Notes
    Perioperative management: Use for pre-operative or peri-operative iron deficiency anemia when documented IDA (eg ferritin <30 ng/mL or ferritin <100 ng/mL with TSAT <20% in inflammation), surgery with expected blood loss >500 mL, and oral therapy is intolerant, ineffective, or there is insufficient time for oral repletion
    Restless leg syndrome: Members 18 years and older with moderate–severe restless legs syndrome when ferritin <=100 ng/mL and TSAT <45% AND unsatisfactory response, intolerance or contraindication to oral iron

    Monoferric (ferric derisomaltose) — Initial approval

    Aetna considers Monoferric medically necessary for the following when criteria are met.

    Adults with IDA

    • Scenarios: Any of: ongoing blood loss (eg heavy uterine bleeding/autologous donation), GI disorders (eg IBD), inability to follow oral regimen, decreased absorption post-gastric surgery
    Monoferric for NDD CKD: Treatment of members 18 years and older with documented iron deficiency anemia and non-dialysis dependent chronic kidney disease (NDD CKD)
    Cancer/chemo-induced anemia when other parenteral irons fail: Management of cancer- and chemotherapy-induced anemia when other parenteral iron preparations fail (eg Feraheme, Ferrlecit, INFeD, Injectafer, Venofer) AND any of: absolute iron deficiency (ferritin <30 ng/mL and TSAT <20%), possible functional (ferritin >500–800 ng/mL and TSAT <50%), or functional with ESA (ferritin 30–500 ng/mL and TSAT <50%) in members receiving myelosuppressive chemotherapy without curative intent

    Feraheme (ferumoxytol) — Initial approval

    Aetna considers Feraheme medically necessary for the following when criteria are met.

    Adults with IDA

    • Scenarios: Any of: ongoing blood loss, GI disorders (eg IBD), nonadherence, post-gastric surgery decreased absorption
    Feraheme for CKD: Treatment of members 18 years and older with documented iron deficiency anemia and a diagnosis of chronic kidney disease (CKD)
    Cancer/chemo-induced anemia: Management of cancer- and chemotherapy-induced anemia when any of: absolute iron deficiency (ferritin <30 ng/mL and TSAT <20%), possible functional (ferritin >500–800 ng/mL and TSAT <50%), or functional with ESA (ferritin 30–500 ng/mL and TSAT <50%) in members receiving myelosuppressive chemotherapy without curative intent

    INFeD (iron dextran) — Initial approval

    Aetna considers INFeD medically necessary for the following when criteria are met.

    Pediatric and adult IDA

    • Scenarios: Any of: ongoing blood loss, GI disorders (eg IBD), nonadherence, post-gastric surgery decreased absorption
    Cancer/chemo-induced anemia: Management of cancer- and chemotherapy-induced anemia when any of: absolute iron deficiency (ferritin <30 ng/mL and TSAT <20%), possible functional (ferritin >500–800 ng/mL and TSAT <50%), or functional with ESA (ferritin 30–500 ng/mL and TSAT <50%) in myelosuppressive chemotherapy without curative intent
    RLS: Members 18 years and older with moderate to severe restless legs syndrome when serum ferritin <=100 ng/mL and TSAT <45% AND unsatisfactory response, intolerance or contraindication to oral iron administration

    Venofer (iron sucrose) — Initial approval

    Aetna considers Venofer medically necessary for the following when criteria are met.

    IDA when oral iron fails

    • Scenarios: Any of: ongoing blood loss, GI disorders, nonadherence, post-gastric surgery decreased absorption
    Venofer for CKD: Treatment of members 2 years of age and older with documented iron deficiency anemia and a diagnosis of chronic kidney disease (CKD)
    Cancer/chemo-induced anemia: Management of cancer- and chemotherapy-induced anemia when any of: absolute iron deficiency (ferritin <30 ng/mL and TSAT <20%), possible functional (ferritin >500–800 ng/mL and TSAT <50%), or functional with ESA (ferritin 30–500 ng/mL and TSAT <50%) in members receiving myelosuppressive chemotherapy without curative intent

    Ferrlecit (sodium ferric gluconate) — Initial approval

    Aetna considers Ferrlecit medically necessary for the following when criteria are met.

    IDA when oral iron fails

    • Scenarios: Any of: members losing iron (eg heavy uterine bleeding/autologous donation), GI disorders (eg IBD), nonadherence, post-gastric surgery decreased absorption
    Ferrlecit for hemodialysis and CKD: Treatment of iron deficiency anemia in members 6 years of age and older with CKD receiving hemodialysis who are receiving supplemental epoetin therapy; also treatment in members with CKD who are not on dialysis>= 6 years for hemodialysis indication
    Cancer/chemo-induced anemia: Management of cancer- and chemotherapy-induced anemia when any of: absolute iron deficiency (ferritin <30 ng/mL and TSAT <20%), possible functional (ferritin >500–800 ng/mL and TSAT <50%), or functional with ESA (ferritin 30–500 ng/mL and TSAT <50%) in members receiving myelosuppressive chemotherapy without curative intent

    Initial Approval — Sodium Ferric Gluconate Complex (Ferrlecit)

    Covered when ANY of the following are met for members with documented iron deficiency anemia and unsatisfactory response/intolerance/contraindication to oral iron:

    ANY of the following

    • Bleeding/High Loss: Members losing iron (blood) at a rate too rapid for oral intake to compensate (includes heavy uterine bleeding and autologous blood donation)
    • GI Disorders: Disorder of the gastrointestinal tract (eg inflammatory bowel disease such as ulcerative colitis and Crohn's disease) where symptoms may be aggravated by oral iron
    • Nonadherence or inability: Members who repeatedly fail to heed instructions for oral iron supplementation or are incapable of accepting or following them
    • Post-gastric surgery/resection: Members with iron deficiency following gastric bypass surgery and/or subtotal gastric resection who exhibited decreased absorption of oral iron

    CKD and Hemodialysis-related Approval

    Covered when ALL of the following are met:

    ALL of the following

    • Age and CKD status: Members age 6 years and older with chronic kidney disease receiving hemodialysis>= 6 years for Ferrlecit hemodialysis indication
    • ESA therapy: Member is receiving supplemental epoetin therapy (eg epoetin alpha, darbepoetin alfa)
    Dosage and administration note: Ferrlecit dosing per product labeling (eg 125 mg per dialysis session for adults; pediatric dose 1.5 mg/kg per session) and may be repeated if iron deficiency recurs

    CKD Not on Dialysis

    Covered indication

    ALL of the following

    • CKD non-dialysis: Treatment of iron deficiency anemia in members with CKD who are not on dialysis

    Cancer- and Chemotherapy-induced Anemia

    Covered when ANY of the following are met:

    ANY of the following

    • Absolute iron deficiency: Ferritin < 30 ng/mL and TSAT < 20% (absolute iron deficiency); may be used with or without an ESAFerritin <30 ng/mL AND TSAT <20%
    • Possible functional iron deficiency: Ferritin >500–800 ng/mL and TSAT <50% with goal of avoiding allogeneic transfusionFerritin >500-800 ng/mL AND TSAT <50%
    • Functional iron deficiency with ESA: Ferritin 30–500 ng/mL and TSAT <50% in members receiving myelosuppressive chemotherapy without curative intent when used in combination with an ESAFerritin 30-500 ng/mL AND TSAT <50%

    Experimental / Not Covered Indications

    Not covered (considered experimental and investigational) when ANY of the following apply:

    ANY of the following

    • Hemochromatosis: Genetic hemochromatosis or hemochromatosis secondary to iron overload (contraindicated/experimental)
    • Other listed indications: Uses such as acute mountain sickness; anemia of inflammation (excludes IBD); anemia of pregnancy or postpartum anemia that do not meet medical necessity criteria; prophylactic use to improve function in non-anemic orthopedic patients; treatment of post-operative anemia following cardiothoracic surgery and neurosurgery that do not meet criteria; and pre-operative IV iron for reduction in need for transfusions from major surgery (excludes abdominal surgery) are considered experimental/investigational

    General coverage criteria (selection-criteria dependent)

    Covered when ALL of the following are met (policy references selection criteria and appropriate ICD-10 diagnoses):

    General indications: IV iron is indicated for treatment of iron deficiency with or without anemia when there is intolerance to oral iron or unsatisfactory response to oral iron, and when appropriate ICD-10 diagnoses (eg iron deficiency anemia, CKD-associated anemia, anemia due to chemotherapy) are present.see ferritin/TSAT thresholds

    Coverage conditioned on meeting selection criteria and appropriate coding

    Not covered indications

    Explicit not-covered conditions: Use of IV iron for acute posthemorrhagic anemia following major surgery (D62) and anemia of inflammation (D63.8) is listed as not covered for indications in the clinical policy bulletin

    Indications for IV iron (clinical criteria)

    Covered when ANY of the following clinical situations apply:

    Indications: - Intolerance to or failure of oral iron therapy (eg gastrointestinal side effects or poor adherence) - Severe iron-deficiency anemia or hemoglobin <10 g/dL - Need for rapid iron repletion when surgery is within ~6 weeks or when prompt correction is required - Malabsorption states (eg post-bariatric surgery, Roux-en-Y, subtotal gastrectomy) leading to refractory deficiency - Adjunct to ESA therapy in cancer-associated or chemotherapy-induced anemia to improve hematologic response and reduce transfusions

    Use of IV iron with ESAs in cancer/chemotherapy-induced anemia

    Covered when ALL of the following are met:

    ESA adjunct criteria: - Patient is receiving an erythropoiesis-stimulating agent for chemotherapy-induced anemia or cancer-associated anemia - Documentation of inadequate hematopoietic response or intent to improve response/reduce transfusion requirement - No contraindication to IV iron

    RCTs and systematic reviews demonstrate improved hematopoietic response and reduced transfusion risk when IV iron is added to ESA therapy

    CIA: IV iron plus ESA vs ESA alone

    Evidence-supported indications and expected benefits

    Cancer-associated/chemotherapy-induced anemia (CIA): Addition of IV iron to ESAs improves hematopoietic response (RR ~1.17 overall; IV subgroup RR ~1.20) and reduces RBC transfusion risk (RR ~0.74) compared with ESA alone based on randomized trials and systematic review; no overall survival benefit demonstrated

    Benefits seen primarily with IV iron rather than oral; evidence quality varies

    CKD (HD, PD, ND) indications

    CKD and dialysis considerations

    CKD hemodialysis: IV iron is commonly required in hemodialysis patients because oral iron often cannot maintain iron balance; regular IV iron use per guidelines can reduce ESA dose (weighted average ~23% reduction) and an initial IV course of approximately 1000 mg is common; consider TSAT and ferritin thresholds
    CKD non-dialysis: For adult CKD patients not on dialysis, consider IV iron (or trial of oral iron for 1–3 months) if TSAT ≤30% and ferritin ≤500 ng/mL when an increase in hemoglobin without ESA is desired; for patients on ESA, consider IV iron if TSAT ≤30% and ferritin ≤500 ng/mL to increase hemoglobin or reduce ESA doseTSAT ≤30%, ferritin ≤500 ng/mL

    Heart failure: IV iron for iron deficiency

    Heart failure with iron deficiency

    HFrEF with iron deficiency: IV ferric carboxymaltose is indicated to improve symptoms, functional capacity (eg 6-minute walk) and quality of life in symptomatic patients with HFrEF and iron deficiency; recommended when ferritin <100 µg/L or ferritin 100–299 µg/L with TSAT <20%Ferritin <100 µg/L or ferritin 100–299 µg/L with TSAT <20%

    ESC gives Class IIa, A recommendation; ACC/AHA indicates it may be reasonable in NYHA II–III

    Heart failure (HFrEF) — IV ferric carboxymaltose

    Evidence-based indications cited in randomized trials and society guidelines:

    HFrEF with iron deficiency: Symptomatic heart failure with reduced EF and iron deficiency defined as ferritin <100 µg/L, or ferritin 100–299 µg/L with TSAT <20%; IV ferric carboxymaltose improved symptoms and exercise capacity in RCTssee ferritin/TSAT thresholds

    Inflammation-associated iron deficiency (including IBD and CKD)

    Diagnostic approach and clinical role of IV iron in inflammatory states:

    Diagnosis in inflammatory states: Use ferritin <100 µg/L or TSAT <20%; when ferritin 100–300 µg/L require TSAT <20% to confirm deficiency; consider adjunct tests (eg CRP, soluble transferrin receptor) given ferritin is an acute phase reactantferritin/TSAT rules
    IV iron role: IV iron is effective for iron deficiency anemia in inflammatory conditions such as IBD and may be preferred when oral iron is ineffective, not tolerated, or when rapid repletion is needed

    Perioperative orthopedic use

    Perioperative IV iron has been studied to reduce allogeneic transfusion and improve outcomes:

    Perioperative IV iron use: Perioperative IV iron (commonly 200–300 mg doses) has been associated with reduced transfusion rates, fewer RBC units, shorter length of stay, and improved recovery in some studies, though RCT evidence is limited and heterogeneous; consider for patients with documented iron deficiency when oral therapy is inadequate or time is insufficient

    Hepcidin testing and role

    Hepcidin biology and testing implications:

    Hepcidin assay utility: Hepcidin assays (eg Intrinsic Hepcidin IDx Test) exist and may aid management of iron-restricted disorders, but lack of standardized assays and biological variability limit routine clinical use

    Evidence-informed coverage considerations

    Summarized findings that would inform coverage decisions:

    Orthopedic peri-operative evidence: Meta-analysis and cohort studies report reductions in transfusion rates and RBC units, shorter length of stay, and some improvements in infections with peri-operative IV iron, but high-quality RCT evidence is limited and heterogeneous
    Pre-operative colorectal/gastrointestinal surgery: Small RCTs show improved hemoglobin with IV iron but inconsistent transfusion reductions; evidence insufficient to support routine pre-operative IV iron for all patients
    Post-operative elective surgery: Systematic reviews show modest increases in mean hemoglobin with IV iron but no consistent improvements in quality of life or transfusion reduction overall
    Post-partum anemia: Some RCTs and reviews show faster hemoglobin and ferritin recovery and improved fatigue with IV iron versus oral iron in postpartum anemia, though evidence quality varies and rare serious events reported

    Coverage criteria for IV iron (pre-operative anemia and RLS)

    Covered when documented ALL of the following are met:

    Pre-operative IV iron — coverage conditions: Patient has documented iron deficiency or iron-deficiency anemia with laboratory evidence (eg low ferritin and/or TSAT) AND there is an identifiable surgical procedure with potential significant blood loss or clinical need for optimization prior to surgery AND either oral iron is not tolerated or effective, or there is insufficient time before surgery to achieve repletion AND baseline hemoglobin and iron studies are documented
    IV iron for RLS — coverage conditions: Patient has moderate-to-severe restless legs syndrome with documented low iron stores (eg ferritin <=100 μg/L or per guideline thresholds) AND intolerance or failure of oral iron OR malabsorption OR need for more rapid response due to severity AND documented baseline ferritin, TSAT and rationale for IV route

    Coverage criteria

    Covered when supported by product-specific FDA indications and clinical conditions such as:

    Coverage rationale: IV iron is covered when used for FDA-approved indications of the specific formulation (eg Triferic/Triferic Avnu for hemodialysis iron replacement; Injectafer, Monoferric, Feraheme, Venofer, INFeD, Ferrlecit per labeling) and when clinical criteria are met
    RLS-specific pathway: For restless legs syndrome, consider iron replacement when fasting serum ferritin <=75 ng/mL; IV iron is generally reserved when ferritin <=100 ng/mL AND one of: malabsorption, complete intolerance to oral iron, moderate-to-severe symptoms despite oral trial, or need for rapid responseferritin <=75–100 ng/mL; TSAT <20% may be used in inflammatory states

    Aetna covers intravenous iron products only for the specific indications and product-specific criteria listed in this policy. All other indications not expressly listed for each product are considered experimental and investigational and are not covered. Providers must document that the requested use meets the policy’s stated medical necessity criteria (including age limits, diagnostic iron studies, and relevant clinical scenarios) for the specific formulation requested.

    Intravenous iron is contraindicated and considered experimental/investigational for select conditions noted in the policy. Examples include genetic hemochromatosis or hemochromatosis secondary to iron overload. Several other uses—such as treatment of anemia of inflammation (excluding IBD), certain pregnancy/postpartum indications that do not meet medical necessity criteria, and pre-operative or post-operative contexts without documented iron deficiency—are classified as investigational unless they meet the specific coverage criteria.

    The policy lists specific exclusions and contraindicated diagnostic codes that may preclude coverage. Notable not-covered ICD-10 codes include D62 (acute posthemorrhagic anemia) and D63.8 (anemia in other chronic diseases), and hemochromatosis codes (E83.110–E83.111). Other excluded scenarios called out in the document are acute mountain sickness, routine prophylactic use in non‑anemic orthopedic patients, and certain post-operative anemia or pre-operative IV iron uses when medical necessity criteria are not met.

    Related HCPCS CodesHCPCS
    J0885Injection, epoetin alfa, (for non-ESRD use), 1,000 units
    J0887Injection, epoetin beta, 1 microgram, (for ESRD on dialysis)
    J0888Injection, epoetin beta, 1 microgram, (for non-ESRD use)
    Q4081Injection, epoetin alfa, 100 units (for ESRD on dialysis)
    ICD-10 Codes (covered if selection criteria met)ICD-10Covered
    D50.0 - D50.9Iron deficiency anemia
    D63.0Anemia in neoplastic disease
    D63.1Anemia in chronic kidney disease
    D64.81Anemia due to antineoplastic chemotherapy
    E83.10Disorder of iron metabolism, unspecified
    N18.1 - N18.9Chronic kidney disease (CKD)
    N18.6End stage renal disease
    ICD-10 Codes Not Covered / ContraindicatedICD-10Not Covered
    D62Acute posthemorrhagic anemia
    D63.8Anemia in other chronic diseases classified elsewhere
    E83.110 - E83.111Hemochromatosis
    Triferic HCPCS codesHCPCS
    J1444Injection, ferric pyrophosphate citrate powder, 0.1 mg of iron
    J1443Triferic solution (existing J-code referenced in document)
    FDA-approved IV iron products and indicationsmixedCovered
    ferumoxytolFeraheme (ferumoxytol) — FDA indication: treatment of iron deficiency anemia in adult patients with chronic kidney disease or intolerance/unsatisfactory response to oral iron.
    sodium ferric gluconate complex in sucroseFerrlecit — treatment of iron deficiency anemia in adults and pediatric patients ≥6 years with CKD receiving hemodialysis and supplemental erythropoietin.
    iron dextranINFeD — treatment of documented iron deficiency when oral administration is unsatisfactory or impossible.
    ferric carboxymaltoseInjectafer — treatment of iron deficiency anemia in adults with non-dialysis-dependent CKD or intolerance/unsatisfactory response to oral iron.
    ferric derisomaltoseMonoferric — treatment of iron deficiency anemia in adults with non-hemodialysis dependent CKD or intolerance/unsatisfactory response to oral iron.
    sodium ferric gluconate complex containing ferric pyrophosphate citrate (dialysate)Triferic — replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent CKD (not intended for peritoneal dialysis).
    ferric pyrophosphate citrate (intravenous use)Triferic Avnu — replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent CKD (not for peritoneal dialysis).
    iron sucroseVenofer — treatment of iron deficiency anemia in patients with chronic kidney disease.
    Ferritin / TSAT thresholds by clinical context
    Non-CKD (adult, general)Ferritin <30 ng/mL OR TSAT <20% confirms iron deficiency anemia
    Non-dialysis CKD (NDD-CKD)Ferritin <100 ng/mL OR TSAT <20%; if ferritin 100–300 ng/mL require TSAT <20%
    Hemodialysis-dependent CKD (HD)Either ferritin ≤200 ng/mL AND TSAT ≤20% OR ferritin <500 ng/mL AND TSAT ≤30% with Hb <10 g/dL or on ESA
    Peritoneal dialysis-dependent CKD (PD)Ferritin ≤100 ng/mL AND TSAT ≤20% OR ferritin ≤500 ng/mL AND TSAT ≤30% with Hb <10 g/dL
    Inflammatory conditions (eg, IBD, CHF, CKD with inflammation)Ferritin <100 ng/mL OR TSAT <20%; if ferritin 100–300 ng/mL require TSAT <20%
    Ferritin and TSAT thresholds for cancer/chemotherapy-induced anemia
    Cancer/Chemotherapy — absolute iron deficiencySerum ferritin <30 ng/mL AND TSAT <20%
    Cancer/Chemotherapy — functional with ESAFerritin 30–500 ng/mL AND TSAT <50% (when used with an ESA)
    Cancer/Chemotherapy — possible functionalFerritin >500–800 ng/mL AND TSAT <50% (possible functional deficiency)
    Ferritin — diagnostic cutoff summary
    Diagnostic ferritin cutoff (absolute ID)Serum ferritin <30 ng/mL is diagnostic of iron deficiency (improves sensitivity vs lower cutoffs)
    Ferritin in inflammationFerritin <50 ng/mL suggests iron deficiency in chronic inflammation; ferritin <100 ng/mL used in many inflammatory contexts
    Ferritin excluding deficiencyFerritin ≥100 ng/mL generally excludes iron deficiency in non-inflammatory settings
    Transferrin saturation (TSAT) — diagnostic cutoff summary
    General TSAT cutoffTSAT <20% commonly used to indicate insufficient iron availability (TSAT <19% cited when ferritin unreliable)
    High-confidence TSATTSAT <10% provides high confidence for iron deficiency
    Expert/alternate thresholdsSome experts use TSAT <16% as a diagnostic threshold in certain contexts
    Hemoglobin exclusion in CONFIRM-HF
    CONFIRM-HF hemoglobin exclusionPatients with hemoglobin ≥15 g/dL were excluded from the CONFIRM-HF trial of ferric carboxymaltose (Injectafer)
    Trial enrollment hemoglobin and ferritin thresholds
    Typical trial Hb enrollment (example)Hemoglobin ≤11 g/dL used as an enrollment threshold in some IV iron trials
    Trial TSAT enrollmentTSAT <20% commonly required for trial eligibility
    Trial ferritin enrollmentSerum ferritin <100 ng/mL used in some trial entry criteria
    Hemoglobin thresholds — perioperative targets and decision points
    Perioperative target hemoglobinTarget preoperative hemoglobin ≥130 g/L (13 g/dL) recommended to minimize transfusion risk
    Severe anemia thresholdIV iron preferred when hemoglobin <10 g/dL or when rapid repletion is needed before surgery
    Timing considerationPostpone major non-urgent surgery to allow anemia diagnosis and treatment when possible
    Ferritin/TSAT thresholds — common diagnostic thresholds
    Absolute iron deficiency (common)Ferritin <30 ng/mL AND TSAT <20% indicate absolute iron deficiency
    Inflammation-adjusted thresholdFerritin <100 μg/L OR ferritin 100–300 μg/L with TSAT <20% used in inflammatory states
    Lower non-inflammatory cutoffsGI guidelines reference lower ferritin cutoffs (eg 15–45 ng/mL) in non-inflammatory settings
    Ferritin and TSAT thresholds — adult/pediatric and CKD thresholds
    Adult CKD (authorization trigger)Consider IV iron when TSAT ≤30% AND ferritin ≤500 ng/mL (adults with CKD)
    Pediatric CKD thresholdsPediatric consideration: TSAT ≤20% AND ferritin ≤100 ng/mL cited for pediatric CKD
    Initial IV iron courseTypical initial total IV iron course ≈1000 mg (may be repeated if needed and thresholds persist)
    Ferritin/TSAT thresholds — inflammation-adjusted operational thresholds
    Inflammation-adjusted operational ruleFerritin <100 µg/L OR ferritin 100–299 µg/L with TSAT <20% commonly used to define iron deficiency in HF/CKD/IBD
    Non-inflammatory low cutoffsIn non-inflammatory settings, lower ferritin cutoffs (eg 15–45 ng/mL) are referenced by some GI guidelines
    TSAT role in inflammationUse TSAT <20% to confirm deficiency when ferritin is between 100–300 µg/L
    Ferritin — assorted cited thresholds across contexts
    Assorted cited ferritin thresholdsFrequently cited thresholds include ≤75 μg/L (RLS consideration), ≤100 ng/mL, <100 ng/mL, and <30 ng/mL for absolute deficiency
    Context-specific notesFerritin ≤75 μg/L suggested for RLS oral therapy consideration; IV generally reserved when ferritin ≤100 μg/L
    Use with TSATFerritin <100 ng/mL with TSAT <20% commonly referenced for iron deficiency in various contexts
    Transferrin saturation (TSAT) — generic cutoff and cautions
    Generic TSAT cutoffTSAT <20% cited as indicative of iron deficiency in many settings
    Upper-limit cautionAvoid iron therapy if %TSAT >45% (RLS guidance)
    Pediatric CKD TSATPediatric CKD threshold cited: TSAT ≤20%
    Ferritin threshold for RLS
    RLS ferritin threshold (consider therapy)Serum ferritin ≤75 ng/mL suggested as threshold to consider iron replacement for restless legs syndrome
    RLS IV consideration thresholdIV iron generally reserved when ferritin ≤100 ng/mL and oral therapy is inappropriate/intolerant or rapid response needed
    RLS TSAT noteTSAT <20% may be more accurate in inflammatory conditions when assessing RLS candidates
    IV iron consideration threshold for RLS
    IV iron consideration for RLSIV iron should be considered for adults with moderate-severe RLS when ferritin ≤100 μg/L and oral therapy is not appropriate or ineffective
    Oral-first for lower ferritinOral iron may be effective for ferritin ≤75 μg/L if tolerated
    Documentation requirementDocument baseline ferritin, TSAT and rationale for IV route
    TSAT — RLS / general cutoff
    TSAT cutoff for RLS/generalTSAT <20% commonly used to indicate low iron stores in RLS and inflammatory settings
    TSAT caution in RLSDo not treat with iron if %TSAT >45% (consensus recommendation)
    Use of TSAT with ferritinUse TSAT to confirm deficiency when ferritin elevated due to inflammation
    Prior Authorization

    Prior Authorization Triggered by J-code Billing

    Coverage for specific IV iron J-codes is conditioned on meeting the policy's selection criteria for those codes (see CPT/HCPCS and criteria sections). Ensure the diagnosis and clinical thresholds align with the indicated J-code being billed.

    • Injectafer (J1439) billed per mg — verify indication and selection criteria
    • Other J-codes must be supported by corresponding clinical criteria in policy
    Billing Rule

    HCPCS Coding for Triferic Products

    Triferic products have distinct HCPCS coding: J1443 describes Triferic solution and J1444 describes Triferic powder packet (0.1 mg iron). Billers must use the correct J-code for the formulation administered; note marketplace availability changes may affect coverage.

    • J1443 — Injection, ferric pyrophosphate citrate solution (Triferic)
    • J1444 — Injection, ferric pyrophosphate citrate powder, 0.1 mg of iron (Triferic powder packet)
    • Triferic/Triferic Avnu were removed from U.S. market in 2022 for business reasons — verify current availability
    Prior Authorization

    Clinical Scenarios That Trigger Prior Authorization

    Prior authorization is typically triggered when IV iron is preferred or required, including: intolerance or inadequate response to oral iron, severe anemia, anticipated imminent surgery (elective surgery within ~6 weeks), malabsorption states (eg post-bariatric surgery), or when rapid repletion is clinically necessary.

    • Oral intolerance, malabsorption, or contraindication to oral iron
    • Severe anemia (eg Hb <10 g/dL) or need for rapid iron repletion before surgery
    • Non-response to oral iron or inability to adhere to oral therapy
    Documentation Required

    Authorization Considerations: TSAT and Ferritin Thresholds

    Authorization decisions incorporate ferritin and TSAT thresholds as operational guides: in CKD and dialysis contexts, IV therapy is commonly considered when TSAT ≤30% and ferritin ≤500 ng/mL; pediatric thresholds may differ and are noted in CKD guidance. For RLS and other conditions, policy references specific ferritin/TSAT cutoffs (eg ferritin ≤75–100 ng/mL and TSAT <20% where applicable).

    • CKD operational thresholds: TSAT ≤30% and ferritin ≤500 ng/mL for repeat IV courses
    • RLS guidance: consider IV iron when ferritin ≤100 ng/mL or ferritin ≤75 ng/mL for oral trial
    • TSAT <20% often used to indicate insufficient iron availability in inflammatory states
    Note

    Note: Guideline/Trial Discussion Without Explicit Authorization Rules

    Some sections of the source contain guideline or trial discussion without explicit authorization rules; when explicit prior authorization criteria are absent, follow the main policy criteria and general documentation requirements.

    • Clinical trial and background text may not establish billing triggers
    • Rely on policy's stated selection criteria and coding sections for authorization decisions
    Documentation Required

    Requirement: Documented Anemia or Iron Deficiency

    Prior authorization requires documented evidence of anemia and/or iron deficiency and a clear clinical rationale for IV iron (eg intolerance to oral iron, malabsorption, ongoing blood loss, or need for rapid repletion). Absent documentation that demonstrates medical necessity, requests risk denial.

    • Require baseline hemoglobin, ferritin, TSAT and clinical explanation for IV therapy
    • Document prior oral iron trial and reasons for failure or intolerance unless exception applies
    Prior Authorization

    Authorization Linked to Product-Specific FDA Indications

    Authorization is aligned with FDA-labeled indications for specific products (eg Feraheme, Injectafer, Monoferric) — approve when the member meets the product-specific FDA indication and policy criteria, and when a lower-cost clinically equivalent alternative is contraindicated, intolerant, or ineffective.

    • Feraheme: FDA-labeled for iron deficiency anemia in adult patients with CKD or intolerance/unsatisfactory response to oral iron
    • Injectafer and Monoferric: approve for FDA-indicated NDD-CKD or intolerance/unsatisfactory response to oral iron
    • Brand selection rules: Feraheme/Injectafer reserved when contraindication/intolerance/inefficacy to preferred products demonstrated
    Denial Risk

    Experimental / Investigational and Contraindicated Uses

    Aetna considers intravenous iron contraindicated or experimental/investigational for select conditions (denial-risk). Notably, intravenous iron is contraindicated in genetic hemochromatosis or hemochromatosis secondary to iron overload, and is considered experimental for a range of other indications where clinical value is unproven.

    • Experimental/Investigational exclusions include: genetic hemochromatosis, anemia of inflammation (excluding IBD), many prophylactic or non-established surgical indications, acute mountain sickness, and certain postpartum/postoperative uses not meeting criteria
    • Intrinsic Hepcidin IDx Test considered experimental for management of iron-restricted/overload disorders
    Denial Risk

    ICD-10 Denial Triggers

    ICD-10 diagnosis codes that are denial triggers for the listed indications include D62 (acute posthemorrhagic anemia) and D63.8 (anemia in other chronic diseases classified elsewhere). If these codes are submitted for indications that the policy does not cover, authorization may be denied.

    • ICD-10 codes listed as not covered for CPB indications: D62, D63.8
    • Confirm that submitted ICD-10 codes match covered indications in the policy
    Documentation Required

    Monitoring and Preparedness for Hypersensitivity

    Serious hypersensitivity and anaphylactic-type reactions can occur with parenteral iron products. Providers must monitor patients during and after infusion until clinically stable and have personnel and therapies immediately available to manage hypersensitivity reactions.

    • Monitor during and after infusion for signs of hypersensitivity, shock, hypotension, loss of consciousness
    • Ensure immediate availability of emergency treatment and trained personnel
    Note

    Perioperative Anemia Assessment and Management

    For perioperative anemia, assess and treat iron deficiency prior to elective major surgery when possible. Consider delaying non-urgent surgery to allow diagnosis and treatment; use serum ferritin and TSAT to guide management and choose oral versus IV iron based on severity and timing.

    • Screen surgical patients for anemia early; target Hb ≥130 g/L preoperatively when feasible for major surgery
    • Prefer oral iron when mild deficiency and time allows; use IV iron for severe deficiency, oral intolerance, or surgery within ~6 weeks
    Documentation Required

    Clinical Thresholds Referenced (Ferritin and TSAT)

    Clinical thresholds referenced throughout the policy include ferritin cutoffs and TSAT values to help define absolute versus functional iron deficiency. Ferritin <30 ng/mL is commonly diagnostic of iron deficiency; higher ferritin thresholds (eg <100 ng/mL) are used in inflammatory states; TSAT <20% often indicates insufficient iron availability.

    • Ferritin <30 ng/mL — diagnostic of iron deficiency in many settings
    • In inflammation/CKD: ferritin <100 ng/mL (or <300 with TSAT considerations) and TSAT <20% used to indicate deficiency
    • TSAT <20% commonly used as operational threshold
    Note

    No Explicit Authorization or Billing Requirement Specified in Some Sections

    Certain portions of the source text contain evidence summaries or references without explicit authorization or billing requirements. When no explicit policy billing rule is specified, follow the main policy criteria and coding tables for authorization and claim adjudication.

    • Do not infer coverage from background evidence summaries alone
    • Refer to the policy's CPT/HCPCS and criteria sections for actionable billing and authorization rules
    Denial Risk

    Potential Denial Risk Where Evidence Is Inconclusive

    Where evidence shows no clear benefit (for example, some post-operative settings), requests for IV iron may be at higher risk of denial unless the member meets the policy's documented medical necessity criteria and supporting clinical documentation is provided.

    • Potential denial risk: pre-operative/post-operative uses with inconclusive evidence for transfusion reduction
    • Ensure robust documentation of indication, labs, and rationale to mitigate denial risk
    Documentation Required

    Pre-Treatment Iron Testing Required

    Do not prescribe IV iron empirically. Pre-treatment iron studies (at minimum serum ferritin and TSAT) are required to assess iron status before IV iron administration. Additional tests (eg CRP, soluble transferrin receptor) may be appropriate when inflammation is present.

    • Obtain baseline ferritin and TSAT prior to IV iron prescribing
    • Consider CRP and soluble transferrin receptor in inflammatory conditions to interpret ferritin
    Denial Risk

    Risk of Denial Without Iron Studies or Clinical Justification

    Requests lacking iron studies (ferritin and TSAT) or adequate clinical justification may be denied. Empiric prescribing without laboratory confirmation of iron deficiency or clear rationale is a common denial trigger.

    • Risk of denial if no baseline ferritin and TSAT documented
    • Provide prior oral iron trial details or documented exception when applicable
    Note

    Administrative Notes / Non-Clinical Content

    Some chunks in the source contain no actionable policy items (administrative or reference-only content). For administrative actions, refer to the Policy History and Additional Information sections and the specialty precertification contact information provided.

    • See Policy History for effective date and next review
    • See Additional Information for contact links and policy notes
    Documentation Required

    Required Clinical Laboratory Documentation for Initial Approval

    Required clinical laboratory documentation for initial approval generally includes baseline hemoglobin (Hb), serum ferritin, and transferrin saturation (TSAT). Where relevant, include CRP, soluble transferrin receptor, reticulocyte hemoglobin content, and other tests to clarify iron status in inflammatory or complex cases.

    • Baseline labs: Hb, ferritin, TSAT (required)
    • Additional recommended tests: CRP, sTfR, CHr, serum iron, TIBC as clinically indicated
    Documentation Required

    Recommended Clinical Monitoring Parameters

    Recommended clinical monitoring parameters include baseline and follow-up hemoglobin, ferritin, TSAT, and monitoring for infusion-related adverse events. Monitor patients during and after infusion for hypersensitivity and report adverse events per standard practice.

    • Baseline and periodic Hb, ferritin, TSAT assessments to evaluate response
    • Observe for infusion reactions during and after administration; document any hypersensitivity
    Documentation Required

    Required Baseline Labs and Timing

    Document baseline labs and timing when evaluating pre-operative anemia or other indications: obtain tests close enough to the planned therapy to reflect current iron status. For repeat IV courses in CKD, document TSAT and ferritin values used to justify re-dosing (eg TSAT ≤30% and ferritin ≤500 ng/mL).

    • Baseline Hb, ferritin, TSAT should be recent and included with prior authorization requests
    • For CKD/dialysis patients, document TSAT ≤30% and ferritin ≤500 ng/mL when applicable
    Note

    Policy History and Administrative Information

    Policy history and additional administrative information (effective date, last review, next review) are maintained in the Policy History and Additional Information sections. The policy effective date is 11/13/2001 with last review 02/01/2024 and next review 12/12/2024. Providers should consult those sections for updates and administrative contacts.

    • Effective: 11/13/2001; Last Review: 02/01/2024; Next Review: 12/12/2024
    • Refer to Additional Information for policy notes and Aetna contact links
    Step Therapy

    Step Therapy: Oral Iron Trial Expectations and Exceptions

    Step therapy preference: when feasible, oral iron should be tried before IV iron for mild deficiency, non-dialysis CKD, and elective perioperative optimization. Exceptions include severe anemia, intolerance or malabsorption, ongoing blood loss, or need for rapid repletion.

    • Oral-first approach expected in non-dialysis CKD when appropriate (trial 1–3 months) and in mild iron deficiency
    • Exceptions: severe anemia (eg Hb <10 g/dL), intolerance to oral iron, malabsorption, or imminent surgery
    Note

    When No Step Therapy Is Specified

    No mandatory step therapy requirements are specified in some policy sections; where the policy does not mandate a specific step, clinicians should provide supporting evidence and rationale for chosen therapy. Comparative evidence exists but does not always impose required step rules.

    • If no step requirement is specified, document clinical justification for IV use
    • Evidence comparisons in background do not equal mandatory step-therapy rules
    Prior Authorization

    Provider Summary: Actions to Support Authorization and Avoid Denials

    In summary, prior authorization and documentation for IV iron require: correct HCPCS/J-code billing, baseline Hb/ferritin/TSAT, documentation of oral iron trial or valid exception, product-specific FDA indication alignment, monitoring plans for hypersensitivity, and awareness of experimental/investigational exclusions and ICD-10 denial triggers to avoid claim denials.

    • Ensure J-code matches product/formulation (eg J1439, J1750, J1756, J2916, J1443, J1444)
    • Provide labs (Hb, ferritin, TSAT), prior therapy history, and rationale for IV iron
    • Confirm indication is not listed as experimental/investigational and ICD-10 codes are appropriate
    Clinical implicationMeets criteria for IV iron consideration when oral therapy inadequate or other indications present
    Functional iron deficiency (examples)
    Functional iron deficiency examplesFerritin 30–500 ng/mL with TSAT <50% (ESA recipients) OR ferritin >500–800 ng/mL with TSAT <50% (possible functional) in cancer/chemo contexts
    Clinical useFunctional ranges guide use of IV iron with ESA or to avoid transfusion in chemo patients
    Trial contextPolicy cites these ranges specifically for chemotherapy-induced anemia pathways
    Ferritin thresholds — diagnostic cutoffs and inflammation adjustments
    Ferritin diagnostic cutoffs summaryFerritin <30 ng/mL diagnostic; ferritin <50 ng/mL suggests deficiency in chronic inflammation; ferritin ≥100 ng/mL generally excludes deficiency
    Sensitivity rationaleUsing cutoff of 30 ng/mL improves sensitivity for iron deficiency diagnosis
    When ferritin unreliableIn inflammatory states use TSAT and higher ferritin thresholds (eg <100) to assess deficiency
    Transferrin saturation (TSAT) — interpretation guidance
    TSAT interpretation generalTSAT <19–20% used when ferritin unreliable; TSAT <10% offers high diagnostic confidence; some experts use <16%
    TSAT roleReflects iron availability for erythropoiesis and used to confirm deficiency when ferritin elevated by inflammation
    Clinical applicationTSAT thresholds inform IV vs oral decisions, especially in inflammatory or CKD settings
    Ferric pyrophosphate citrate (FPC) — mechanism and delivery
    FPC mechanism and deliveryFerric pyrophosphate citrate (FPC) donates iron directly to transferrin; available as dialysate (Triferic) and IV (Triferic Avnu)
    IndicationUsed to replace ongoing iron losses in hemodialysis-dependent CKD without increasing ferritin markedly
    Coding noteCMS established HCPCS codes J1443 and J1444 for Triferic formulations
    Ferric derisomaltose (Monoferric) — product description and labeled use
    Product description and labeled useFerric derisomaltose (Monoferric) indicated for IDA in adults intolerant or unresponsive to oral iron and for non-hemodialysis dependent CKD
    Trial dosingTrials enrolled adults with Hb ≤11 g/dL, TSAT <20% and s-ferritin ≤100 ng/mL (or ≤300 if TSAT ≤30%)
    Administration noteMonoferric can be given as single 1000 mg infusion in some regimens
    Ferric carboxymaltose (Injectafer) — product description and typical uses
    Injectafer description and usesFerric carboxymaltose (Injectafer) is used for rapid IV iron repletion including perioperative anemia, IBD-related IDA, RLS, and cancer/chemotherapy-induced anemia
    Safety notesInjectafer carries warnings for hypersensitivity, symptomatic hypophosphatemia and hypertension; serious anaphylactic reactions reported (0.1% in trials)
    Heart failure indication specificsCONFIRM-HF used ferritin <100 ng/mL or 100–300 with TSAT <20% to define iron deficiency for treatment to improve exercise capacity
    Venofer (iron sucrose) — product description
    Venofer descriptionVenofer (iron sucrose) is an aqueous complex of polynuclear iron(III)-hydroxide in sucrose used IV to treat iron deficiency when oral iron fails or is not tolerated
    Common usesUsed in IBD, CKD, post-bariatric surgery malabsorption, and chemotherapy-associated anemia
    Safety profileWarnings include hypersensitivity, hypotension and iron overload; common adverse reactions listed in product labeling
    Absolute and functional iron deficiency (NCCN definitions)
    NCCN operational definitions (cancer)Absolute iron deficiency: ferritin <30 ng/mL and TSAT <20%; functional with ESA: ferritin 30–500 ng/mL and TSAT <50%; possible functional: ferritin >500–800 ng/mL and TSAT <50%
    Clinical implicationThese ranges guide IV iron use with ESAs in chemotherapy-induced anemia
    Consistency notePolicy aligns NCCN definitions with coverage pathways for cancer/chemo-induced anemia
    Iron deficiency laboratory thresholds (CKD context)
    CKD lab thresholds summaryCKD contexts commonly use ferritin thresholds ≤100–200 µg/L and TSAT <20%; consider IV iron when TSAT ≤30% and ferritin ≤500 ng/mL
    Peritoneal dialysis noteFor PD patients, IV iron recommended for Hb <10 g/dL with TSAT ≤30% and ferritin ≤500 ng/mL
    Practice noteInitial IV iron course often ≈1000 mg; repeat if TSAT ≤30% and ferritin ≤500 ng/mL persist
    Iron deficiency in inflammatory states (operational thresholds)
    Inflammation-adjusted thresholdsFerritin <100 µg/L OR ferritin 100–299 µg/L with TSAT <20% commonly used to define iron deficiency in inflammatory states (CHF, CKD, IBD)
    Adjunct testsConsider CRP, soluble transferrin receptor, or other adjunct assays when inflammation may affect ferritin
    Clinical role of IV ironIV iron preferred when oral iron ineffective or not tolerated in inflammatory disease settings
    Intrinsic Hepcidin IDx Test — brief definition and intended use
    Intrinsic Hepcidin IDx Test (definition)A monoclonal antibody-based quantitative competitive ELISA intended to aid management of iron-restricted disorders and iron-overload conditions
    Clinical utilityAssay may inform management but lack of standardized assays limits routine clinical use
    Application noteHepcidin testing not yet recommended for broad routine decision-making in this policy
    Peri-operative IV iron therapy (IVIT) — definition
    Peri-operative IV iron therapy (definition)Administration of IV iron in the pre-, intra- or post-operative period intended to correct iron deficiency/anemia and potentially reduce allogeneic transfusion
    Typical doses in orthopedic studiesCommon reported doses 200–300 mg per administration in peri-operative orthopedic trials
    Evidence noteMeta-analyses show reduced transfusion proportion and shorter LOS but RCT evidence heterogeneous; large trials pending
    Pre-operative anemia — definition used in reviewed RCTs
    Pre-operative anemia definition (trial context)Anemia defined as Hb <13 g/dL in males and <12 g/dL in non-pregnant females in reviewed RCTs
    Cochrane scopePre-operative trials included small RCTs (eg colorectal, gynecologic) with mixed results on transfusion reduction
    ImplicationPre-op anemia management aims to optimize Hb to reduce transfusion risk perioperatively
    Iron deficiency (commonly used thresholds)
    Commonly used iron deficiency thresholds (concise)Ferritin <100 ng/mL OR TSAT <20% commonly used; for RLS ferritin ≤75 μg/L (oral) or ≤100 μg/L (IV consideration)
    RLS specificsFor RLS consider oral iron if ferritin ≤75 μg/L; reserve IV iron generally when ferritin ≤100 μg/L and oral not appropriate
    Clinical applicationThresholds vary by context (CKD, inflammation, cancer) and should be interpreted with clinical picture
    Low ferritin for RLS — threshold to consider iron replacement
    Low ferritin for RLS (oral therapy threshold)Serum ferritin ≤75 ng/mL suggested as threshold to consider iron replacement for restless legs syndrome
    IV reserved threshold for RLSIV iron generally reserved when ferritin ≤100 ng/mL and oral therapy unsuitable or symptoms moderate-severe
    Documentation guidanceObtain fasting serum ferritin, TIBC and %TSAT before treatment; avoid iron if %TSAT >45%
    TSAT — definition and use (<20% indicative in inflammatory settings)
    TSAT role and cutoffTSAT <20% may be a more accurate measure of low iron stores in inflammatory disorders and is commonly used to indicate deficiency
    TSAT cautionDo not use iron therapy if %TSAT >45% (RLS guidance)
    Complementary useUse TSAT alongside ferritin in contexts where ferritin may be elevated by inflammation